Skip to main content
Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes

Fig. 2

Comparison of the International Prognostic Scoring System-Revised (IPSS-R) and the International Prognostic Scoring System-Molecular (IPSS-M). A The restratification of IPSS-R to IPSS-M for 852 patients with MDS. Vertical axis represents IPSS-R categories and horizontal axis represents IPSS-M categories. The proportion of patients in each category is shown in Additional file 1: Table S6. B, C The percentage of restratified patients in each IPSS-R stratum, counting either any shift or cases with more than one shifts. D The association between the number of mutated IPSS-M main effect adverse genes and patient reclassification. Abbreviations: MDS: myelodysplastic syndrome; BM: bone marrow; IPSS-R: International Prognostic Scoring System-Revised; IPSS-M: International Prognostic Scoring System-Molecular

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us